SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-039115
Filing Date
2020-08-11
Accepted
2020-08-11 07:09:13
Documents
72
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q prvl-10q_20200630.htm 10-Q 2734773
2 EX-5.1 prvl-ex51_386.htm EX-5.1 20034
3 EX-10.1 prvl-ex101_532.htm EX-10.1 261687
4 EX-31.1 prvl-ex311_6.htm EX-31.1 18636
5 EX-31.2 prvl-ex312_7.htm EX-31.2 18610
6 EX-32.1 prvl-ex321_8.htm EX-32.1 17889
7 GRAPHIC gv0bon4h3mq1000001.jpg GRAPHIC 28720
  Complete submission text file 0001564590-20-039115.txt   8387060

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT prvl-20200630.xml EX-101.INS 1557813
9 XBRL TAXONOMY EXTENSION SCHEMA prvl-20200630.xsd EX-101.SCH 50457
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE prvl-20200630_cal.xml EX-101.CAL 45845
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE prvl-20200630_def.xml EX-101.DEF 212346
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE prvl-20200630_lab.xml EX-101.LAB 424922
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prvl-20200630_pre.xml EX-101.PRE 347198
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Filer) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38939 | Film No.: 201091039
SIC: 2836 Biological Products, (No Diagnostic Substances)